Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 33 results found. Search for [ India vaccine emergency use authorization ]

Results 1 to 21 of 33
Associated Press
March 3, 2021
White House press secretary Jen Psaki also announced Tuesday that the federal government was increasing supply of the Moderna and Pfizer vaccines to states next week to 15.2 million doses per week, up from 14.5 million previously


BusinessToday.In
New Delhi, February 5, 2021
Pfizer Inc has withdrawn its application for emergency-use authorization of its COVID-19 vaccine in India that it had developed with Germany's BioNTech. The US company, which was the first drugmaker to apply for emergency use authorization of its coronavirus vaccine in India, had a meeting with the country's drugs regulator on Wednesday and the decision was made after that, the company said. India's Central Drugs Standard Control Organisation had declined to accept Pfizer's request for approval without a small local trial on the vaccine's safety and immunogenicity for Indians. Watch the video for more.Also Read: Pfizer withdraws emergency use application for COVID-19 vaccine in India


BusinessToday.In
January 11, 2021
Pfizer is yet to submit additional data sought by India authorities regarding its COVID-19 vaccine for granting emergency use approval to it; the company has missed last three SEC meetings too


BusinessToday.In
January 5, 2021
COVID-19 vaccine update: India has approved two coronavirus vaccines for emergency use - Bharat Biotech-ICMR's Covaxin and Covishield manufactured by Pune's Serum Institute


BusinessToday.In
December 26, 2020
Pune-based SII is to submit an updated safety data of phase 2 and 3 clinical trials in India, immunogenicity data from the clinical trial in the UK and India, as well as the assessment results of the UK Medicines and Healthcare products Regulatory Agency


Reuters
December 23, 2020
The Indian government is considering emergency use authorization for three vaccine candidates - one from AstraZeneca, another from Pfizer, and a separate one developed by the Indian firm Bharat Biotech


BusinessToday.In
December 21, 2020
More than Rs 7 lakh crore of investor wealth was eroded in a single session as Sensex fell 2,037 points to 44,923, its day's low and Nifty lost 628 points to the intraday low of 13,131


BusinessToday.In
December 13, 2020
As of December 11, Mexico remains the fourth worst-affected country by the pandemic in the world.


BusinessToday.In
December 12, 2020
US President Donald Trump says: \"We've delivered a safe and effective vaccine in just 9 months. This is one of the greatest scientific accomplishments in history\"


BusinessToday.In
December 9, 2020
\"The fundamental that went into the pricing was that we make sure we make it very quickly available to everyone,\" said Pfizer.


Aseem Thapliyal
December 9, 2020
While Sensex rose 556 points to 46,164, Nifty climbed 156 points to 13,558


Reuters
December 9, 2020
 Union health secretary said there are multiple vaccine candidates in different stages of development and some may get licensed in the next few weeks


PTI
December 8, 2020
Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation


PTI
December 8, 2020
All India Bank Officers' Confederation (AIBOC), All India Bank Officers' Association (AIBOA), Indian National Bank Officers' Congress (INBOC) and National Organisation of Bank Officers (NOBO) have jointly written the letter to the finance minister


BusinessToday.In
December 6, 2020
\"During this pandemic phase, Pfizer will supply this vaccine only via government contracts based on agreements with respective govt authorities & following regulatory authorization or approval\", the US pharma firm said


Reuters
December 5, 2020
WHO's top emergency expert Mike Ryan also cautioned against complacency in the wake of vaccine roll-out, adding although they were a major part of the battle against COVID-19, vaccines would not on their own end the pandemic


Reuters
November 28, 2020
Poonawalla said in the next few weeks SII plans to apply for emergency use authorization for AstraZeneca's COVID-19 vaccine candidate that he described as a 'very good' option


BusinessToday.In
November 21, 2020
Pfizer's CEO Albert Bourla confirmed the company's application and said in a video statement,  'It is with great pride and joy - and even a little relief - that I can say that our request for emergency use authorization for our COVID-19 vaccine is now in the FDA's hands.'


BusinessToday.In
November 16, 2020
Moderna stated that its COVID-19 vaccine candidate remains stable for 30 days at 2-degree Celsius to 8-degree Celsius, the temperature of a standard home or medical refrigerator


BusinessToday.In
November 10, 2020
The domestic currency opened up at 74.04 per US dollar at the interbank forex market, although, edged slightly lower to 74.05 in early deals, rising 10 paise over its last close


PAGES 1 OF 2  12